ÂÜÀòÂÒÂ×

Deniz Simsek Buck, PhD has a diverse work experience in the field of scientific research and development. Starting in 2006, Deniz worked as a PHD student at Cornell University, specializing in their chosen field. Following the completion of their PhD, Deniz worked at the UCSF Medical Center as a Damon Runyon Cancer Foundation Research Fellow from 2011 to 2013. Deniz then moved to Stanford University, where they served as a Postdoctoral Researcher from 2013 to 2016.

In 2016, Deniz joined Amgen as a Scientist, where they designed experimental strategies for the transfer of large molecules across the blood-brain barrier and played a key role in ribosome profiling for target discovery. They also focused on target discovery in solid tumors for combinatorial targeting to reduce the associated toxicities of T-cell engagers.

Deniz continued their work at Amgen until 2021 when they transitioned to Teneobio, Inc. (which later merged with Amgen). At Teneobio, Deniz held the position of Senior Scientist and was responsible for the preclinical development of T-cell engagers. They also contributed to the IND readiness for a co-stimulatory molecule and served as the biology lead for two solid tumor T-cell engagers.

Most recently, in 2023, Deniz Simsek Buck joined Interline Therapeutics as a Principal Scientist.

Deniz Simsek Buck, PhD pursued their education in a chronological order, starting with their Bachelor of Science degree in Biological and Biomedical Sciences from Sabanci University, which they obtained from 2002 to 2006. Deniz Simsek then went on to Weill Cornell Graduate School of Medical Sciences, where they completed their Doctor of Philosophy (PhD) in Molecular Biology and Genetics from 2006 to 2011.